Autolus Therapeutics (AUTL) took a hit today, dropping over 17%. They reported preliminary 2025 revenue around $75M and issued 2026 guidance between $120M and $135M. They also secured approvals in the UK and EU for AUCATZYL. Despite the regulatory wins, the market sold off. The stock is trading at $1.50, while some analyst models suggest a fair value near $9.60. The gap seems to come from concerns about high manufacturing costs and potential delays in getting access to European markets.